0HB0.L
Agios Pharmaceuticals, Inc. [0HB0.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0HB0.L Stock Summary
Top 10 Correlated ETFs
0HB0.L
In the News
0HB0.L Financial details
Company Rating
-
Market Cap
1.66B
Income
-352.09M
Revenue
26.82M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
383
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-6.02
Forward P/E
-
PEG
-1.21
P/S
55.08
P/B
1.49
P/C
-
P/FCF
-4.55
Quick Ratio
11.1
Current Ratio
12.06
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-6.34
EPS next Y
-
EPS next Q
-
EPS this Y
49.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.6%
Revenue last 5Y
-25.63%
Revenue Q/Q
-4%
EPS Q/Q
4.88%
-
-
-
-
SMA20
4.76%
SMA50
15.79%
SMA100
29.41%
Inst Own
-
Inst Trans
-
ROA
-22%
ROE
-22%
ROC
-0.41%
Gross Margin
-1687%
Oper. Margin
-1600%
Profit Margin
-914%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
20.13-35.3493
52W High
+28.6%
52W Low
+125.05%
RSI
66
Rel Volume
-
Avg Volume
522
Volume
2
Perf Week
9.19%
Perf Month
11.14%
Perf Quarter
51.04%
Perf Half Y
55.53%
-
-
-
-
Beta
0.855
-
-
Volatility
0.95%, 1.51%
Prev Close
-1.06%
Price
45.01
Change
1.17%
Company Profile
- Volume Average 522
- Market Capitalization 1.66B
- Employee 383
- CEO Mr. Brian M. Goff M.B.A.
- Headquarters Cambridge,MA,US
- IPO Date 2018-01-29
-
Website
https://www.agios.com 
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
